Formaldehyde treatment is a method routinely used to detoxify diphtheria, tetanus, and pertussis toxins as well as other molecules suitable for vaccine production. To investigate whether chemical detoxification alters the immunological properties of vaccine components, we have treated the pertussis toxin mutant PT-9K/129G with formaldehyde and tested the properties of the resulting molecules. Very low concentrations of formaldehyde stabilize the molecule without affecting the physicochemical and immunological parameters. Increasing doses of formaldehyde abolish the mitogenic and hemagglutinating activities of PT-9K/129G. At the same time, the molecule loses the ability to be recognized by a monoclonal antibody specific for a major protective epitope on the Sl subunit of pertussis toxin and its affinity for anti-pertussis toxin polyclonal antibodies is also reduced. In marked contrast, the ability of PT-9K/129G to be recognized by human T-cell clones is not affected by Formalin treatment. In vivo, the formaldehyde-treated molecules induce amounts of specific antibodies comparable with those of untreated molecules but significantly lower levels of toxinneutralizing antibodies. Furthermore, the formaldehyde-treated !molecules also show a reduced protective activity in the intracerebral challenge assay.
Formaldehyde treatment was introduced in 1923 (4, 14) to detoxify diphtheria toxin for vaccine use. Since then, this method has been successfully used for inactivation of tetanus, diphtheria, and pertussis toxins (PT) and preparation of many bacterial and viral vaccines. Such vaccines have proved to be very efficacious, and their use has been instrumental in the eradication of several diseases. One of the few drawbacks of chemical treatment is that chemically inactivated toxoids can revert to toxicity (18) ; therefore, each vaccine lot has to undergo extensive testing before use. With the advent of biotechnology, molecular genetics has provided new tools to inactivate toxins for vaccine use. In fact, it is now possible to modify one or more codons in their genes and obtain naturally nontoxic molecules which do not need chemical treatment and have no risk of reversion to toxicity (12) . We have recently constructed genetically detoxified PT mutants and tested them in preclinical (10, 12) and phase I clinical (13) studies as potential vaccines against whooping cough. PT is a protein composed of five different subunits. Subunit S1 (A protomer), which is responsible for toxicity, is an enzyme with ADP-ribosyltransferase activity. Subunits S2, S3, S4, and S5 form the nontoxic B oligomer which binds to receptors on the surface of eucaryotic cells. The nontoxic mutant (PT-9K/129G) used in this study is enzymatically inactive and devoid of any toxic activity but maintains the ability to bind to receptors on eucaryotic cells.
Not only are genetically inactivated molecules safer theoretically in that there is no possibility of subsequent reversion to toxicity but results obtained so far have shown that they may also be superior immunogens compared with chemically detoxified molecules (6) . In fact, even when using doses of the genetically engineered vaccine which are lower than those previously described for chemically detoxified molecules (16, 17, 20) , we have obtained higher levels of toxin-neutralizing antibodies in adult volunteers (13 
MATERIALS AND METHODS
Preparation of PT, PT-9K/129G, and B oligomer. PT, PT-9K/129G, and the B oligomer of PT were obtained and purified from the culture supernatants of wild-type strain Bordetella pertussis W28, recombinant strain B. pertussis W28-9K/129G expressing the double S1 mutation Arg-9-*Lys and Glu-129--*Gly (10, 12) , and recombinant strain B.
pertussis W28-8D/9G engineered to secrete only the B oligomer (11) (8) , and their patterns were estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) by the method of Laemmli (7) and Western blot (immunoblot) analysis (11) .
Hemagglutination. The hemagglutination assay was performed as previously described (15) After 3 h at room temperature, the plates were extensively washed, the wells were cut out, and the bound radioactivity was counted in a gamma counter. Each sample was analyzed in duplicate. PT was iodinated by the standard chloramine T procedure. The data were analyzed by a nonlinear regression analysis, and the affinity constant was calculated as previously described (9 by using S1-specific human CD4-positive T-cell clones (1, 2) . The clones tested were T215, S106, S105, and S223, which recognize S1 peptides 27-39, 30-41, 180-194, and 212-235, respectively (1). The T-cell recognition assay was performed essentially as previously described (1, 2 ELISA. The enzyme-linked immunosorbent assay (ELISA) was performed as previously described (10) . Briefly, wells of flat-bottomed polystyrene microtest plates (Costar) were coated with PBS (pH 7.4) containing 10 ,ug of purified PT or purified B oligomer and incubated for 2 h at 37°C and overnight at 4°C in a humidified chamber. After incubation of fivefold dilutions of guinea pig serum samples, specific alkaline phosphatase-conjugated immunoglobulin G antibodies (Miles, Yeda, Israel) were added to the wells. PBS (100 ,ul) (pH 7.4) was used in all steps, and incubations were performed at 37°C for 2 h. Three washings of the plates with PBS containing 0.05% Tween 20 and 0.02% NaN3 were carried out between each incubation.
The enzyme substrate reaction which developed at room temperature after the addition of 1 mg ofp-nitrophenylphosphate per ml in 1 M diethanolamine (pH 9.8) containing 0.5 mM MgCl2 was measured at 405 mm in a Titertek Multiskan (Flow Laboratories, McLean, Va.). Antitoxin antibody levels were expressed as geometric mean absorbance values of undiluted sera (ABS-MAX) from guinea pigs tested individually.
Toxin neutralization. The ability of the antibodies raised in guinea pigs to neutralize the clustering effect of PT on Chinese hamster ovary (CHO) cells was evaluated essentially as previously described (3, 5, 10) . Briefly, sera from guinea pigs obtained after vaccination with one or two doses of Formalin-treated preparations of PT-9K/129G were directly diluted in the wells of flat-bottomed microplates (Costar) in 25 ,ul of Dulbecco modified Eagle medium (DMEM; Flow Laboratories). Purified wild-type PT (120 pg) in 25 i,l of DMEM was added to each well, and the plates were incubated for 3 h at 37°C. After the incubation period, 0.2 ml of DMEM containing 104 CHO cells, previously treated with 1 mg of trypsin per ml, was added to each well and incubated for 48 h at 37°C in 5% CO2 atmosphere. As a positive control, the clustering effect of PT alone was determined in each plate. Neutralizing titers were expressed as the reciprocal of the highest serum dilution causing complete inhibition of the clustering activity induced by the wild-type toxin.
Immunogenicity. Groups of six white guinea pigs were inoculated intradermally with 3 or 25 ,ug of the Formalintreated PT-9K/129G preparations adsorbed onto aluminium hydroxide (0.5 mg/dose). Four weeks later, the animals were bled and given booster doses identical to the doses given at the first immunization. Two weeks after the booster doses, sera were collected and tested by ELISA for antitoxin titers and toxin-neutralizing activity in the CHO cell assay.
Vaccine potency. Groups of 16 male CD1 mice were vaccinated intraperitoneally according to the World Health Organization recommendations (19) with 0.5 ml of diphtheria-pertussis-tetanus vaccine containing PT-9K/129G preparations treated with 0.035 (Fl), 0.070 (F4), and 0.420% (F8) formaldehyde as the pertussis component. Fourteen days later, mice were injected intracerebrally with 300 median lethal doses deriving from a suspension of virulent B. pertussis 18323 (Sclavo, Siena, Italy). Mice were observed for 14 days and deaths were recorded.
RESULTS
Formaldehyde treatment of PT-9K/129G. Eight samples, each containing 5 mg of PT-9K/129G, were treated with doses of formaldehyde ranging from 0.035 to 0.420% (wt/vol) for 48 h at 37°C as described in Materials and Methods and summarized in Table 1 . Five micrograms of each sample was then loaded onto a polyacrylamide gel to test the effect of chemical treatment on the SDS-PAGE profile of PT-9K/ 129G. Treatment with increasing doses of formaldehyde proportionally changed the natural electrophoretic pattern (Fig. la) . The overall pattern, composed of subunits S1 (A protomer) and S2, S3, S4, and S5 (B oligomer), was not changed by low doses of formaldehyde. However, bands with molecular weight higher than that of S1, which by Western blot analysis were shown to be composed mainly of multimers of the B-oligomer subunits, were already visible at the lower Formalin dose and increased in intensity at higher specific for the S1 subunit. The results (Fig. 2) (Fig. 3) . In fact, after the first immunization, all sera showed the same level of anti-PT antibodies as FO, which increased after the second injection. However, while-antibodies obtained from samples treated with low doses of formaldehyde recognized PT and to a lower extent the B oligomer (Fig. 3) , the antibodies obtained from samples treated with high doses of formaldehyde recognized the B oligomer and PT at the same level. Interestingly, the change in specificity of the antibodies correlated with a decrease in the toxin-neutralizing titers of the antibodies obtained; samples treated with low doses of formaldehyde had neutralizing titers above 1/1,280, whereas samples treated with high doses of formaldehyde were unable to neutralize the toxin activity at dilutions above 1/160 (Fig. 4) . We conclude that while the total amount of antibodies is not affected by Formalin treatment, the fine specificity and the properties of the antibodies obtained are altered.
Vaccine potency. We next studied the ability of some Formalin-treated preparations of PT-9K/129G to protect mice from a lethal intracerebral infection with virulent B. We have shown that Formalin treatment alters in a dosedependent fashion the electrophoretic pattern, biological properties such as the mitogenic and the hemagglutinating activities, and also the affinity of the molecule for antibodies raised against the native toxin (10). An interesting finding has been the observation that after Formalin treatment of the holotoxin, the immunodominant protective epitope located in the S1 subunit and recognized by many monoclonal antibodies becomes unavailable for antibody binding. However, this epitope is likely to be masked by the subunits of the B oligomer, since it can be detected in a Western blot, when the Si subunit is no longer complexed with the other subunits (Fig. lb) . In marked contrast, the T-cell epitopes also located in the S1 subunit are not affected by Formalin treatment. These observations correlate well with the immunogenic properties of the molecules. In fact, the immune system was equally stimulated by native or Formalin-treated antigens, and the total amount of antibodies produced and presumably cellular immunity were not affected by Formalin treatment. However, the specificity and quality of the antibodies produced changed; samples treated with higher Formalin concentrations produced predominantly anti-B oligomer antibodies which were unable to neutralize the native toxin in vitro. The protective activity of the antigen in the intracerebral challenge assay was also decreased in a dosedependent fashion by treating the molecule with formaldehyde. These (10) . Such treatment can be very useful for vaccine preparations.
